What Are the Ethical Issues Around Placebo-Controlled Trials for Terminally Ill Patients?

Placebo-controlled trials for patients with a terminal illness typically present complex ethical considerations. These trials have the potential to provide valuable data and lead to the development of new treatments, but are not without potential harm. Patients in the control group of trials (those who receive a placebo) are likely to be denied a potentially life-extending or life-saving treatment. And while they are already likely going to die from their condition, the treatment may extend their lives for some time. This may conflict with the ethical principle of beneficence.

Additionally, sometimes patients with certain terminal illnesses can access experimental drugs through expanded access or “compassionate use”. Expanded access allows patients with rare or life-threatening diseases to receive treatment with a medication not approved by the FDA, often outside a clinical trial. However, drug manufacturers involved in clinical trials may determine that providing patients with expanded access to experimental medications is unethical while trial participants are receiving a placebo. Similarly, participants in a trial may have their autonomy limited if they are required to use only the trial medication and avoid other potentially beneficial treatments. 

A final consideration surrounds informed consent. Patients participating in clinical trials should fully understand that they may receive a placebo before agreeing to participate. However, patients with terminal illnesses may experience compromised decision-making capacity due to their circumstances and the symptoms of their condition. Some ethicists believe that providers should evaluate a participant’s decision-making capacity before enrolling them in a study to ensure the patients know what they are agreeing to.

Placebo-controlled trials involving terminal patients can quickly become a complicated ethical dilemma, depending on the circumstances. While these trials have significant potential to achieve the greater good through medical innovation, ensuring that core principles are maintained can be challenging. Ultimately, these studies should aim to maximize the potential advantages of clinical research while emphasizing the reduction of harm to patients who are vulnerable due to end-stage disease or a terminal prognosis. 

Sources 

“Placebo—To be or not to be? Are there really alternatives to placebo-controlled trials?” European Neuropsychopharmacology. https://www.sciencedirect.com/science/article/pii/S0924977X19318917 

“How Patients with Terminal Illnesses Get Access to Experimental Drugs”. Brain & Life. https://www.brainandlife.org/articles/patients-terminal-illnesses-access-experimental-drugs